News

Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Menezes R, Gregoricchio S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden MS, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci A et al. (2025)
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer
Cell Rep Med, 102215 (in press)
DOI 10.1016/j.xcrm.2025.102215, PubMed 40609538

Thulin MH, Ramberg H, Nielsen HK, Grytli HH, Sivanesan S, Pandya AD, Seip K, Andressen KW, Linder A, Øijordsbakken M, Poutanen M, Katz B, Halvorsen B, Mælandsmo GM, Taskén KA (2025)
Beta-blockers prolong response to androgen deprivation therapy in prostate cancer through modulation of the neuro-immuno-oncology axis
J Transl Med, 23 (1), 672
DOI 10.1186/s12967-025-06644-7, PubMed 40528241

Bouska A, Zhang W, Sharma S, Holte H, Shah RA, Lone WG, Soma MA, Yang R, Liu X, Mehmood S, Chawla RS, Cappelli LV, Fiore D, Gong Q, Heavican-Foral TB, Cannatella JJ, Amador C, Arif A, Smith LM, Lim ST, Ong CK, Feldman AL, Du MQ, Perry AM, de Leval L et al. (2025)
Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma
Am J Hematol (in press)
DOI 10.1002/ajh.27736, PubMed 40510016